{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:10:50Z","timestamp":1793329850748,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01211-1","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T14:38:18Z","timestamp":1736865498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Fedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and \u201creal-world\u201d data"],"prefix":"10.1038","volume":"15","author":[{"given":"Adrian","family":"Duek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5606-0980","authenticated-orcid":false,"given":"Ilona","family":"Leviatan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osnat","family":"Jarchowsky Dolberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-1472","authenticated-orcid":false,"given":"Martin H.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"1211_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","volume":"35","author":"M Talpaz","year":"2021","unstructured":"Talpaz M, Kiladjian JJ. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Leukemia. 2021;35:1\u201317.","journal-title":"Leukemia"},{"key":"1211_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ccell.2017.12.007","volume":"33","author":"Q Jiang","year":"2018","unstructured":"Jiang Q, Jamieson C. BET\u2019ing on dual JAK\/BET inhibition as a therapeutic strategy for myeloproliferative neoplasms. Cancer Cell. 2018;33:3\u20135.","journal-title":"Cancer Cell"},{"key":"1211_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","volume":"33","author":"M Kleppe","year":"2018","unstructured":"Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, et al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell. 2018;33:29\u201343.e7.","journal-title":"Cancer Cell"},{"key":"1211_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","volume":"29","author":"A Pardanani","year":"2011","unstructured":"Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29:789\u201396.","journal-title":"J Clin Oncol"},{"key":"1211_CR5","doi-asserted-by":"crossref","unstructured":"Pardanani A, Tefferi A, Jamieson C, Gabrail NY, Gao G, Liu F, et al. A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. Blood Cancer J. 2015;5:e335.","DOI":"10.1038\/bcj.2015.63"},{"key":"1211_CR6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1:643\u201351.","journal-title":"JAMA Oncol"},{"key":"1211_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/bjh.17727","volume":"195","author":"A Pardanani","year":"2021","unstructured":"Pardanani A, Tefferi A, Masszi T, Mishchenko E, Drummond M, Jourdan E, et al. Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. Br J Haematol. 2021;195:244\u20138.","journal-title":"Br J Haematol"},{"key":"1211_CR8","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","volume":"4","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu FV, Zachee P, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4:e317\u2013e324.","journal-title":"Lancet Haematol"},{"key":"1211_CR9","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/ajh.25777","volume":"95","author":"CN Harrison","year":"2020","unstructured":"Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, Silver RT, et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol. 2020;95:594\u2013603.","journal-title":"Am J Hematol"},{"key":"1211_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/bjh.18207","volume":"198","author":"CN Harrison","year":"2022","unstructured":"Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Passamonti F, Zweegman S, et al. Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts. Br J Haematol. 2022;198:317\u201327.","journal-title":"Br J Haematol"},{"key":"1211_CR11","doi-asserted-by":"crossref","unstructured":"Gupta V, Yacoub A, Mesa RA, Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial. Leuk Lymphoma. 2024;65:1314\u201324.","DOI":"10.1080\/10428194.2024.2346733"},{"key":"1211_CR12","doi-asserted-by":"publisher","first-page":"e729","DOI":"10.1016\/S2352-3026(24)00212-6","volume":"11","author":"CN Harrison","year":"2024","unstructured":"Harrison CN, Mesa R, Talpaz M, Al-Ali HK, Xicoy B, Passamonti F, et al. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Haematol. 2024;11:e729\u2013e40.","journal-title":"Lancet Haematol"},{"key":"1211_CR13","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1182\/blood-2023-173391","volume":"142","author":"CN Harrison","year":"2023","unstructured":"Harrison CN, Mesa R, Talpaz M, Al-Ali HK, Xicoy B, Passamonti F, et al. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: results from the phase 3 randomized FREEDOM2 study. Blood. 2023;142:3204\u201304.","journal-title":"Blood"},{"key":"1211_CR14","doi-asserted-by":"crossref","unstructured":"Isfort S, von Bubnoff N, Al-Ali HK, Becker H, Gotze T, le Coutre P, et al. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN). Ann Hematol. 2024;103:8:2775\u201385.","DOI":"10.1007\/s00277-024-05867-w"},{"key":"1211_CR15","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1111\/bjh.18284","volume":"198","author":"N Gangat","year":"2022","unstructured":"Gangat N, McCullough K, Al-Kali A, Begna KH, Patnaik MM, Lizow MR, et al. Limited activity of fedratinib in myelofibrosis patients relapsed\/refractory to ruxolitinib 20\u2009mg twice daily or higher: a real-world experience. Br J Haematol. 2022;198:e54\u2013e58.","journal-title":"Br J Haematol"},{"key":"1211_CR16","doi-asserted-by":"publisher","first-page":"1980.","DOI":"10.1182\/blood-2021-145573","volume":"138","author":"J Mascarenhas","year":"2021","unstructured":"Mascarenhas J, Gerds AT, Kee A, Kish JK, Abraham P, Balanean A, et al. Clinical outcomes at 3 and 6\u2009months of fedratinib therapy following prior ruxolitinib failure: real-world assessment of spleen, symptoms, and hematologic response. Blood. 2021;138:1980.","journal-title":"Blood"},{"key":"1211_CR17","doi-asserted-by":"crossref","unstructured":"Jain T, Katzen H, Zeng J, Nguyen H, Aton L, Qureshi P et al. MPN-070 real-world clinical outcomes in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX). Clin Lymphoma Myeloma Leuk. 2024;23:S379.","DOI":"10.1016\/S2152-2650(23)01212-0"},{"key":"1211_CR18","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.2217\/fon-2022-1256","volume":"20","author":"F Passamonti","year":"2024","unstructured":"Passamonti F, Lou Y, Chevli M, Abraham P. Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis. Future Oncol. 2024;20:1165\u201374.qqa","journal-title":"Future Oncol"},{"key":"1211_CR19","doi-asserted-by":"crossref","unstructured":"Passamonti F, Parikh RC, Korgaonkar S, Chevli M, Staff S, Rombi J, et al. Patient characteristics, treatment patterns, and health outcomes in a real-world population of patients with myelofibrosis treated with fedratinib. 2024. https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper173420.html","DOI":"10.1182\/blood-2023-173420"},{"key":"1211_CR20","doi-asserted-by":"crossref","unstructured":"Duek A, Tzinman A, Maziuk K, Levy, A, Ellis MH, Stemer G, et al. Outcomes of fedratinib in routine treatment of ruxolitinib-resistant or -refractory patients with primary and post-polycythemia vera or essential thrombocythemia myelofibrosis: a nationwide retrospective study. 2024. https:\/\/www.wjgnet.com Accessed 7 Sep 2024","DOI":"10.1159\/000540906"},{"key":"1211_CR21","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1038\/s41375-024-02330-7","volume":"38","author":"S Koschmieder","year":"2024","unstructured":"Koschmieder S, Bose P, Ellis MH, Gupta V, Kiladjian JJ, Masccerhanes J, et al. Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group. Leukemia. 2024;38:1831\u20138.","journal-title":"Leukemia"},{"key":"1211_CR22","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ajh.26857","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, andmanagement. Am J Hematol. 2023;98:801\u201321.","journal-title":"Am J Hematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01211-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01211-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01211-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T14:38:22Z","timestamp":1736865502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01211-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1211"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01211-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}